|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 84.66 USD | +1.13% |
|
+4.47% | -15.01% |
| 11:54am | Fda approves Bravecto Quantum, a long-acting injectable for dogs 6 months and older | RE |
| 11:30am | Morgan Stanley Adjusts Price Target on Merck to $98 From $99, Maintains Equalweight Rating | MT |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Operating Income: Breakdown by Business Segment
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
Pharmaceutical Products | ||||||||||
Pharmaceutical | 43.02B | 42.75B | 52B | 53.58B | 57.4B | |||||
D&A | 690M | 6M | 5M | 5M | 5M | |||||
Operating Income | 29.72B | 30.98B | 36.85B | 38.88B | 44.53B | |||||
Veterinary Drugs | ||||||||||
Animal Health | 4.7B | 5.57B | 5.55B | 5.62B | 5.88B | |||||
D&A | 164M | 158M | 177M | 198M | 256M | |||||
Operating Income | 1.65B | 1.95B | 1.96B | 1.74B | 1.94B | |||||
Unallocated Other Revenues | 247M | 382M | 1.73B | 907M | 891M | |||||
Operating Income | 140M | 156M | 1.16B | -3.57B | -4.27B | |||||
D&A | 1M | - | - | - | - | |||||
Operating Income | -13.07B | -11.69B | -13.01B | -30.01B | -17.35B | |||||
Operating Income | -1.6B | -1.41B | -1.64B | -1.62B | -1.84B | |||||
Operating Income | - | -1.64B | -2.08B | -2.04B | -2.4B | |||||
Pharmaceutical Contract Manufacturing Services | ||||||||||
Other profits | 23M | - | - | - | - | |||||
D&A | - | - | - | - | - | |||||
Operating Income | 1M | - | - | 474M | 492M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
United States | 21.03B | 22.42B | 27.21B | 28.48B | 32.28B | |||||
Total Assets | 10.53B | 11.76B | 12.89B | 13.92B | 14.72B | |||||
Europe, Middle East and Africa | 13.6B | 13.34B | 14.49B | 13.25B | 14.04B | |||||
Total Assets | 6.06B | 6.08B | 6.99B | 7.56B | 7.55B | |||||
China | 3.62B | 4.38B | 5.19B | 6.8B | 5.49B | |||||
Total Assets | 217M | 220M | 207M | 193M | 202M | |||||
Latin America | 2.27B | 2.21B | 2.58B | 3.09B | 3.46B | |||||
Total Assets | 252M | 199M | 225M | 222M | 133M | |||||
Japan | 3.38B | 2.73B | 3.63B | 3.16B | 3.28B | |||||
Total Assets | 166M | 159M | 135M | 133M | 143M | |||||
Asia Pacific (other than China and Japan) | 2.86B | 2.41B | 3.61B | 3.22B | 3.06B | |||||
Total Assets | 761M | 857M | 966M | 1.02B | 982M | |||||
Other | 1.23B | 1.22B | 2.57B | 2.1B | 2.56B | |||||
Total Assets | 5M | 4M | 5M | 4M | 47M | |||||
Asia Pacific | - | - | - | - | - | |||||
Total Assets | - | - | - | - | - |
- Stock Market
- Equities
- MRK Stock
- Financials Merck & Co., Inc.
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition